Table I.
Author | Year | Study* | Cut-off mm | Rationale† | Study duration months | Groups |
|||||
---|---|---|---|---|---|---|---|---|---|---|---|
Placebo |
Active |
||||||||||
N | % Progressors |
N (‡) | % Progressors |
||||||||
Compl | ITT | Compl | ITT | ||||||||
Pavelka | 2000 | 1 | 0.5 | 1 | 60 | 60 | 62 | 22 | 60 (3) | 24 | 10 |
Chevalier | 2001 | 2 | 0.6 | 2 | 12 | 29 (3) | 34.1 | ||||
Dougados | 2001 | 1 | 0.5 | 2 | 36 | 225 | 62.3 | 60.4 | 221 (3) | 50.7 | 47 |
Lane | 2004 | 2 | 0.5 | 1 | 96 | 745 (2) | 46 | ||||
Reijman | 2005 | 2 | 1 | 1 | 72 | 1905 (1) | 13.1 | ||||
Reijman | 2007 | 2 | 1 | 1 | 72 | 1676 (1) | 8.7 |
ITT: intent-to-treat population; Compl: completers’ population.
Study: 1 = randomized placebo controlled trial; 2 = epidemiological study.
Rationale: 1 = arbitrary proposal; 2 = proposal based on the reliability of technique of measurement of JSW.
Patients: 1 = population; 2 = hip OA population; 3 = hip OA painful-population.